Chung-Ze Wu1, Li-Chien Chang2, Yuh-Feng Lin3, Yi-Jen Hung4, Dee Pei5, Nain-Feng Chu6, Jin-Shuen Chen7. 1. Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC; Division of Endocrinology and Metabolism, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan, ROC. 2. School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, ROC. 3. Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, ROC; Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan, ROC. 4. Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. 5. Department of Internal Medicine, Cardinal Tien Hospital, Xindian, Medical School, Catholic Fu Jen University, Taipei, Taiwan, ROC. 6. Superintendent, Taitung Hospital, Ministry of Health and Welfare, Taiwan, ROC; School of Public Health, National Defense Medical Center, Taipei, Taiwan, ROC. 7. Division of Nephrology, Department of Internal Medicine, Tri-service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC. Electronic address: dgschen@ndmctsgh.edu.tw.
Abstract
OBJECTIVES: Soluble urokinase plasminogen activator receptor (suPAR), derived from membrane bound uPAR, is associated with inflammatory diseases. In the present study, we explored the expression of uPAR/suPAR in common biopsy-proven kidney diseases and the relationship between suPAR and staging of type 2 diabetic nephropathy (DN). DESIGN AND METHODS: Serum samples for suPAR and renal tissues for uPAR staining were investigated in various common kidney diseases. The levels of serum suPAR were measured and adequate cut-off values of different stage of DN were calculated by receiver operating characteristic (ROC) curve. RESULTS: In our results, the expression of uPAR on renal tissues was pronounced in the majority of kidney diseases. Comparing of expression of uPAR among different kidney diseases, it was strongest in minimal change disease (MCD) and weakest in chronic interstitial nephritis. Serum suPAR in most kidney diseases, except of MCD, was significantly elevated and was highest in DN. As for DN and suPAR, we found that suPAR progressively increased with staging of DN. Moreover, suPAR was linearly and negatively related to estimated glomerular filtration rate and positively related to the amount of proteinuria. By ROC curve, the cut-off values of suPAR in DN for assessing development increased with the progression of the disease. CONCLUSIONS: We concluded that uPAR/suPAR is elevated in most kidney diseases and that suPAR is a useful biomarker for assessing stages of DN.
OBJECTIVES: Soluble urokinase plasminogen activator receptor (suPAR), derived from membrane bound uPAR, is associated with inflammatory diseases. In the present study, we explored the expression of uPAR/suPAR in common biopsy-proven kidney diseases and the relationship between suPAR and staging of type 2 diabetic nephropathy (DN). DESIGN AND METHODS: Serum samples for suPAR and renal tissues for uPAR staining were investigated in various common kidney diseases. The levels of serum suPAR were measured and adequate cut-off values of different stage of DN were calculated by receiver operating characteristic (ROC) curve. RESULTS: In our results, the expression of uPAR on renal tissues was pronounced in the majority of kidney diseases. Comparing of expression of uPAR among different kidney diseases, it was strongest in minimal change disease (MCD) and weakest in chronic interstitial nephritis. Serum suPAR in most kidney diseases, except of MCD, was significantly elevated and was highest in DN. As for DN and suPAR, we found that suPAR progressively increased with staging of DN. Moreover, suPAR was linearly and negatively related to estimated glomerular filtration rate and positively related to the amount of proteinuria. By ROC curve, the cut-off values of suPAR in DN for assessing development increased with the progression of the disease. CONCLUSIONS: We concluded that uPAR/suPAR is elevated in most kidney diseases and that suPAR is a useful biomarker for assessing stages of DN.
Authors: Shengyuan Luo; Josef Coresh; Adrienne Tin; Casey M Rebholz; Teresa K Chen; Salim S Hayek; Melissa Tracy; Michael S Lipkowitz; Lawrence J Appel; Andrew S Levey; Lesley A Inker; Jochen Reiser; Morgan Erika Grams Journal: Clin J Am Soc Nephrol Date: 2018-06-14 Impact factor: 8.237
Authors: Martina Guthoff; Robert Wagner; Elko Randrianarisoa; Erifili Hatziagelaki; Andreas Peter; Hans-Ulrich Häring; Andreas Fritsche; Nils Heyne Journal: Sci Rep Date: 2017-01-16 Impact factor: 4.379
Authors: Lívia Helena de Morais Pereira; Crislaine Aparecida da Silva; Maria Luíza Gonçalves Dos Reis Monteiro; Liliane Silvano Araújo; Laura Penna Rocha; Marcelo Bernardes da Rocha Reis; Fernando Silva Ramalho; Rosana Rosa Miranda Corrêa; Marcos Vinicius Silva; Marlene Antonia Reis; Juliana Reis Machado Journal: PLoS One Date: 2019-06-12 Impact factor: 3.240